HBOT for Radiation Injury: 2026 Cancer Survivor Outcomes & Clinical Data

Radiation Injury: A Growing Patient Population

For every 4-5 radiation injury patients treated with HBOT, one achieves complete symptom resolution they would not have reached otherwise. That number-needed-to-treat figure, drawn from a 2023 systematic review of 38 studies, makes HBOT one of the most effective interventions for late radiation tissue injury. Roughly half of all cancer patients receive radiation, and the vascular damage it causes is progressive, often surfacing months or years after treatment ends. This is one of several HBOT applications in cancer care currently under clinical review.

HBOT for radiation tissue injury is one of the most established and well-supported indications in hyperbaric medicine, classified among the 14 FDA-cleared indications and covered by Medicare and most private insurers. The evidence base spans a 2023 Cochrane review, multiple meta-analyses, and the largest radiation injury treatment registry ever assembled.

Types of Radiation Injury Treated with HBOT

Osteoradionecrosis (ORN)

ORN occurs when radiation-damaged bone loses its blood supply and begins to die, most commonly in the mandible (jaw) after head and neck cancer radiation. The 2023 Cochrane review found HBOT achieved mucosal coverage at RR 1.3 (95% CI 1.1-1.6, p=0.003, NNTB 5) and reduced ORN wound breakdown risk at RR 4.2 (95% CI 1.1-16.8, p=0.04, NNTB 4).¹

• Resolution without surgery: 60-75% of stage I-II ORN
• Marx protocol: Pre- and post-operative HBOT around dental procedures in irradiated bone reduces ORN risk from ~30% to less than 5%
• Typical protocol: 30 sessions pre-procedure + 10 sessions post-procedure at 2.0-2.4 ATA

Radiation Cystitis

Radiation cystitis (bladder damage from pelvic radiation) causes hematuria, urgency, and frequency. A 2024 meta-analysis of 556 patients confirmed 89.9% symptom improvement and 55% complete remission of hematuria (95% CI 51-59%).⁴ The largest systematic review (815 patients) found 87.3% overall response and 65.3% complete response.⁵

• Complete resolution of hematuria: 55-65%
• Overall symptom improvement: 84-90%
• Typical protocol: 30-40 sessions at 2.0-2.4 ATA
• Recurrence rate: ~14%; repeat HBOT is effective

Radiation Proctitis

Radiation damage to the rectum from pelvic radiation causes bleeding, pain, and bowel dysfunction. The Cochrane review found a relative risk of 1.72 (95% CI 1.0-2.9, p=0.04) for improvement or cure, with a number needed to treat of 5.¹

• Symptom improvement: 65-75%
• Cessation of rectal bleeding: 60-70%
• Typical protocol: 30-40 sessions at 2.0-2.4 ATA

Soft Tissue Radionecrosis

Radiation damage to soft tissues can cause chronic wounds, fibrosis, and tissue breakdown. The Cochrane review found surgical flap survival improved dramatically with HBOT (RR 8.7, 95% CI 2.7-27.5, p=0.0002, NNTB 4), one of the most striking numbers in the entire evidence base.¹

• Healing rate: 60-75% for soft tissue radionecrosis
• Breast LRTI: 85% improvement at 12 months in a case series of 67 patients⁸
• Typical protocol: 40-60 sessions at 2.0 ATA

The Mechanism: Reversing Vascular Damage

Radiation damages blood vessels progressively through a process called endarteritis obliterans: the progressive thickening and closure of small blood vessels. This creates a “3H” tissue environment: Hypoxic (low oxygen), Hypocellular (few cells), and Hypovascular (few blood vessels).

HBOT reverses each component:

1. Hyperoxygenation: Immediately delivers oxygen to hypoxic tissue at 10-15x normal levels
2. Angiogenesis: Repeated sessions stimulate new blood vessel formation, creating a lasting vascular network
3. Cellular repair: Improved oxygenation supports fibroblast activity, collagen synthesis, and tissue remodeling

The angiogenesis effect is key. A 30-60 session course produces lasting vascular changes that permanently improve tissue health. Unlike treatments that address only symptoms, HBOT targets the underlying pathology that radiation created.

Cochrane Review Outcomes at a Glance

“The number needed to treat is remarkably low: for every 4-5 patients treated with HBOT for radiation tissue injury, one additional patient achieves a significant clinical benefit compared to standard care alone.”
Cochrane Review, Lin et al., 2023

What Does the HBOT Protocol Look Like?

Durability of HBOT Outcomes

Long-term data increasingly supports the durability of HBOT benefits. Five-year follow-up from the RICH-ART trial showed that approximately 69% of patients who responded to HBOT for radiation-induced urinary symptoms maintained their improvements, with 12.8% requiring a repeat HBOT course.⁹ In breast cancer radiation injury, significant improvements in pain, fibrosis, and shoulder mobility persisted at 12 months after completing HBOT.⁸ For radiation cystitis, the recurrence rate is approximately 14%, and repeat HBOT courses are often effective for those who do recur.

“Five-year follow-up data now confirm what shorter studies suggested: HBOT-driven improvements in radiation injury symptoms are durable, with nearly 70% of responders maintaining their gains over the long term.”
RICH-ART Trial, 2025

Does Insurance Cover HBOT?

Radiation injury HBOT has among the most reliable insurance coverage of any indication:

• Medicare: Covered under NCD 20.29 for delayed radiation injury of soft tissue and bone
• Private insurance: Generally covered with prior authorization; many insurers have specific pathways for radiation injury referrals from oncologists
• Referral pathway: Typically radiation oncologist or urologist refers to HBOT center, with supporting documentation of radiation history and tissue damage

References

1. Lin Z, Bennett MH, Hawkins G, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2023;8:CD005005. DOI: 10.1002/14651858.CD005005.pub5. PMID: 37585677.
2. Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev. 2018;4:CD005007. DOI: 10.1002/14651858.CD005007.pub4. PMID: 29637538.
3. Niezgoda JA, Serena T, Carter MJ. Outcomes of Radiation Injuries Using Hyperbaric Oxygen Therapy. Adv Skin Wound Care. 2016;29(1):12-19. DOI: 10.1097/01.ASW.0000473679.29537.c0. PMID: 26650092.
4. Yang TK, et al. Efficacy and Safety of HBOT for Radiation-Induced Hemorrhagic Cystitis. J Clin Med. 2024;13(16):4724. DOI: 10.3390/jcm13164724. PMID: 39200867.
5. Villeirs L, et al. Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy. Int J Urol. 2019;26(12):1145-1156. DOI: 10.1111/iju.14130. PMID: 31617263.
6. Cardinal JR, et al. Scoping Review and Meta-analysis of HBOT for Radiation-Induced Hemorrhagic Cystitis. Curr Urol Rep. 2018;19(9):79. DOI: 10.1007/s11934-018-0790-3. PMID: 29654564.
7. El Hadji S, Teguh D, Ridderikhof M. HBOT for late radiation tissue toxicity injury after head and neck cancer. Radiat Oncol. 2025;20:54. DOI: 10.1186/s13014-025-02680-1. PMID: 41044659.
8. Spruijt NE, van den Berg R. The effect of HBOT on late radiation tissue injury after breast cancer. Diving Hyperb Med. 2020;50(3):206-213. DOI: 10.28920/dhm50.3.206-213. PMID: 32957121.
9. RICH-ART Trial 5-Year Follow-Up. PMC12033922. 2025. Patient-reported urinary symptom improvements sustained over 5 years; 68.6% of responders maintained benefit.
10. Eckert KA, Fife CE, Carter MJ. Systematic Review of Hyperbaric Oxygen for Late Radiation Tissue Injury (Bowel, Bladder). Undersea Hyperb Med. 2025. DOI: 10.22462/754. PMID: 41223393.
11. Andren J, Bennett MH. An observational trial to establish the effect of HBOT on pelvic LRTI. Diving Hyperb Med. 2020;50(3):250-255. DOI: 10.28920/dhm50.3.250-255. PMID: 32957127.
12. Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries. Undersea Hyperb Med. 2002;29(1):4-30. PMID: 12507182.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website